Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Rafiemanesh H, Mehtarpour M, Khani F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis. 2016;8:1094–1102.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Z, Ding X, et al. ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Sci Rep. 2015;5:11392.
   PubMed Web of Science ®Google Scholar
• Leung YK, Mak P, Hassan S, et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA. 2006;103:13162–13167.
   PubMed Web of Science ®Google Scholar
• Tang H, Liao Y, Xu L, et al. Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int J Cancer. 2013;133:2473–2482.
   PubMed Web of Science ®Google Scholar
• Vallath S, Hynds RE, Succony L, et al. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J. 2014;44:513–522.
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol J Eur Soc Med Oncol. 2004;15:28–32.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Hsu LH, Liu KJ, Tsai MF, et al. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci. 2015;106:51–59.
   PubMed Web of Science ®Google Scholar
• Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998;247:75–78.
   PubMed Web of Science ®Google Scholar
• Wei YH, Tang HX, Liao YD, et al. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer. J Huazhong Univ Sci Technol Med Sci. 2015;35:834–841.
   PubMed Web of Science ®Google Scholar
• Liang J, Zheng S, Xiao X, et al. Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR/Ca2+/calpain/ITGbeta4 axis. Biol Open. 2017;6:914–922.
   PubMed Web of Science ®Google Scholar
• Liu Z, Liao Y, Tang H, et al. The expression of estrogen receptors beta2, 5 identifies and is associated with prognosis in non-small cell lung cancer. Endocrine. 2013;44:517–524.
   PubMed Web of Science ®Google Scholar
• Shen H, Yuan Y, Sun J, et al. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharm Biomed. 2010;64:88–92. pharmacotherapie.
   PubMed Web of Science ®Google Scholar
• Ambrogio C, Barbacid M, Santamaria D. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene. 2017;36:2309–2318.
   PubMed Web of Science ®Google Scholar
• Li TQ, Hong XQ, Zhao J, et al. Gelsolin-like actin-capping protein is associated with patient prognosis, cellular apoptosis and proliferation in prostate cancer. Biomarkers Med. 2016;10:1251–1260.
   PubMed Web of Science ®Google Scholar
• Rouf R, MacFarlane EG, Takimoto E, et al. Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. JCI Insight. 2017;2:pii: 91588.
   Web of Science ®Google Scholar
• Surin AM, Sharipov RR, Krasil’nikova IA, et al. Disruption of functional activity of mitochondria during MTT assay of viability of cultured neurons. Biochemistry (Mosc). 2017;82:737–749.
   PubMed Web of Science ®Google Scholar
• Sun BB, Fu LN, Wang YQ, et al. Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. J Diges Dis. 2014;15:491–500.
   PubMed Web of Science ®Google Scholar
• Misharin AV, Morales-Nebreda L, Mutlu GM, et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013;49:503–510.
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang GB, Yin SW. Effect of bortezomib on migration and invasion in cervical carcinoma HeLa cell. Asian Pac J Trop Med. 2015;8:485–487.
   PubMed Web of Science ®Google Scholar
• Hershberger PA, Stabile LP, Kanterewicz B, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol. 2009;116:102–109.
   PubMed Web of Science ®Google Scholar
• Huff MO, Todd SL, Smith AL, et al. Arsenite and cadmium activate MAPK/ERK via membrane estrogen receptors and G-protein coupled estrogen receptor signaling in human lung adenocarcinoma cells. Toxicol Sci. 2016;152:62–71. an official journal of the Society of Toxicology.
   PubMed Web of Science ®Google Scholar
• Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;162:2141–2150.
   Google Scholar
• Lee TG, Jeong EH, Min IJ, et al. Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors. Oncol Lett. 2017;14:2191–2197.
   PubMed Web of Science ®Google Scholar
• Tong CWS, Wu WKK, Loong HHF, et al. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett. 2017;405:100–110.
   PubMed Web of Science ®Google Scholar
• Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2008;7:9.
   PubMedGoogle Scholar
• Miyawaki M, Yasuda H, Tani T, et al. Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer. Mol Cancer Res. 2017;15:106–114.
   PubMed Web of Science ®Google Scholar
• Pinton G, Thomas W, Bellini P, et al. Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One. 2010;5:e14110.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Frackelton AR, Jr, et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16:70–84.
   PubMed Web of Science ®Google Scholar